http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103830250-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9a78da8f42e62ea3c3cee540fee2673 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635 |
| filingDate | 2012-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d90dd7e593fd73cb70d368bf5d66b6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a36925f757fc45959a5a3dad9769c223 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9925ddd0606ad9c9b22e93f566f7722a |
| publicationDate | 2014-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103830250-A |
| titleOfInvention | Preparation method of compound sulfachloropyrazine sodium suspension |
| abstract | The invention belongs to the technical field of veterinary drugs and discloses a preparation method of a compound sulfachloropyrazine sodium suspension. The suspension comprises sulfachloropyrazine sodium, sodium hydroxyethyl cellulose, tween-80, EDTA-Na2, a synergist, a preservative and a solubilizer. The preparation method comprises the steps of mixing 1/3 volume dose of solubilizer with the preservative, and then adding the sodium hydroxyethyl cellulose; adding the rest solubilizer into the EDTA-Na2, adding water for dilution, and finally adding the sulfachloropyrazine sodium and stirring for dissolution; mixing the solutions, adding the tween-80 and suspending with the synergist to obtain the compound sulfachloropyrazine sodium suspension. According to the method disclosed by the invention, by selecting scientific suspending aid, solubilizer, preservative and metal complexing agent, the medicine of the dosage form does not generate accumulative precipitate after long-time standing, so that the medicine is uniformly distributed in an aqueous phase and can be synchronously absorbed in an administration process, thus the disease treatment requirements are met, and the treatment effect is sufficiently realized. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105267148-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105267148-A |
| priorityDate | 2012-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.